BRIEF-Corcept Receives Complete Response Letter For Relacorilant As A Treatment For Patients With Hypercortisolism

Reuters2025-12-31

Dec 31 (Reuters) - Corcept Therapeutics Inc CORT.O:

CORCEPT RECEIVES COMPLETE RESPONSE LETTER FOR RELACORILANT AS A TREATMENT FOR PATIENTS WITH HYPERCORTISOLISM
CORCEPT THERAPEUTICS INC - FDA ISSUES COMPLETE RESPONSE LETTER FOR RELACORILANT NDA
CORCEPT THERAPEUTICS INC - FDA REQUIRES ADDITIONAL EVIDENCE FOR RELACORILANT APPROVAL

Source text: ID:nBw1PW1h4a

Further company coverage: CORT.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2595771281?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-31 21:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595771281","market":"us","top_or_hot":-1,"title":"BRIEF-Corcept Receives Complete Response Letter For Relacorilant As A Treatment For Patients With Hypercortisolism","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Corcept Receives Complete Response Letter For Relacorilant As A Treatment For Patients With Hypercortisolism</title></head><body><p><span>Dec 31 (Reuters)</span><span> - </span>Corcept <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>CORT.O</span>:</p><ul><li><p>CORCEPT RECEIVES COMPLETE RESPONSE LETTER FOR RELACORILANT AS A TREATMENT FOR PATIENTS WITH HYPERCORTISOLISM</p></li><li><p>CORCEPT THERAPEUTICS INC - FDA ISSUES COMPLETE RESPONSE LETTER FOR RELACORILANT NDA</p></li><li><p>CORCEPT THERAPEUTICS INC - FDA REQUIRES ADDITIONAL EVIDENCE FOR RELACORILANT APPROVAL</p></li></ul><p>Source text: <span>ID:nBw1PW1h4a</span></p><p>Further company coverage: <span>CORT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Corcept Receives Complete Response Letter For Relacorilant As A Treatment For Patients With Hypercortisolism</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Corcept Receives Complete Response Letter For Relacorilant As A Treatment For Patients With Hypercortisolism\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-31 21:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Corcept Receives Complete Response Letter For Relacorilant As A Treatment For Patients With Hypercortisolism</title></head><body><p><span>Dec 31 (Reuters)</span><span> - </span>Corcept <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>CORT.O</span>:</p><ul><li><p>CORCEPT RECEIVES COMPLETE RESPONSE LETTER FOR RELACORILANT AS A TREATMENT FOR PATIENTS WITH HYPERCORTISOLISM</p></li><li><p>CORCEPT THERAPEUTICS INC - FDA ISSUES COMPLETE RESPONSE LETTER FOR RELACORILANT NDA</p></li><li><p>CORCEPT THERAPEUTICS INC - FDA REQUIRES ADDITIONAL EVIDENCE FOR RELACORILANT APPROVAL</p></li></ul><p>Source text: <span>ID:nBw1PW1h4a</span></p><p>Further company coverage: <span>CORT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nTUA6DTLZX:1","article_id":"2595771281","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595771281","pubTimestamp":1767186365,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Corcept Receives Complete Response Letter For Relacorilant As A Treatment For Patients With HypercortisolismDec 31 (Reuters) - Corcept Therapeutics Inc CORT.O:CORCEPT RECEIVES COMPLETE RESPONSE ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU0566484027.USD":"安本美国小盘成长股","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","BK4532":"文艺复兴科技持仓","CORT":"Corcept医疗"},"translate_title":"BRIEF-Corcept收到Relacorilant治疗皮质醇增多症患者的完整回复函","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":0.9},"content_text":"BRIEF-Corcept Receives Complete Response Letter For Relacorilant As A Treatment For Patients With HypercortisolismDec 31 (Reuters) - Corcept Therapeutics Inc CORT.O:CORCEPT RECEIVES COMPLETE RESPONSE LETTER FOR RELACORILANT AS A TREATMENT FOR PATIENTS WITH HYPERCORTISOLISMCORCEPT THERAPEUTICS INC - FDA ISSUES COMPLETE RESPONSE LETTER FOR RELACORILANT NDACORCEPT THERAPEUTICS INC - FDA REQUIRES ADDITIONAL EVIDENCE FOR RELACORILANT APPROVALSource text: ID:nBw1PW1h4aFurther company coverage: CORT.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595771281","isCrawlerRequest":true}